ReNeuron Group plc announced that following on from the original Fosun Pharma licensing agreement announced on 9 April 2019, the Company has signed an additional agreement with Fosun, on 5 January 2022, setting out the first steps in the potential technology transfer of the CTX drug product for the stroke disability programme. The agreement allows for £320,000 to be invoiced on signing with further payments expected, based on services and CTX cell bank vials to be supplied by ReNeuron in the future, although these are contingent on signing a supplemental payment terms agreement which is currently under discussion. ReNeuron will update the market further once agreement on these terms have been reached.